Table 2.
Practice patterns in the treatment of multiple myeloma.
| Variable | Entire Study Population | 2006–2010 Cohort | 2011–2016 Cohort |
|---|---|---|---|
| Treated with HDT-ASCT | 28% | 24% | 32% |
| Most common regimen | RD (n = 156) | RD (n = 89) | RD (n = 67) |
| Second most common regimen | VD (n = 107) | VD (n = 65) | PD (n = 56) |
| Third most common regimen | VRD (n = 87) | VRD (n = 50) | Dara (n = 46) |
| Most common regimen in first line of therapy | VD (n = 68) | VD (n = 43) | ACVDL (n = 40) |
| Most common induction therapy in HDT-ASCT-eligible patients | ACVDL (n = 23) | VD (n = 11) | ACVDL (n = 18) |
| Most common 1st line therapy in HDT-ASCT-ineligible patients | VD (n = 49) | VD (n = 36) | ACVDL (n = 22) |
| Most common regimen in second line of therapy | RD (55) | RD (n = 26) | RD (n = 29) |
| Most common regimen in third line of therapy | RD (n = 34) | RD (n = 24) | PD (n = 22) |
| Patients treated with bortezomib | 85% | 83% | 86% |
| Patients treated with lenalidomide | 78% | 70% | 84% |
| Patients treated with pomalidomide | 38% | 20% | 55% |
| Patients treated with daratumumab | 33% | 20% | 45% |
| Patients treated with carfilzomib | 18% | 9% | 27% |
| Reason for discontinuation of treatment: progressive disease | 33% | 29% | 36% |
| Reason for discontinuation of treatment: fixed-duration regimen | 19% | 23% | 14% |
| Reason for discontinuation of treatment: toxicity | 18% | 20% | 16% |
| Reason for discontinuation of treatment: insufficient response | 17% | 12% | 22% |
| Reason for discontinuation of treatment: death | 6% | 7% | 5% |
| Reason for discontinuation of treatment: patient's choice | 3% | 5% | 2% |
| Reason for discontinuation of treatment: plateau phase | 2% | 3% | 2% |
| Reason for discontinuation of treatment: poor performance status | 2% | 2% | 2% |
| Reason for discontinuation of treatment: other | <1% | <1% | <1% |
| Time on treatment/survival ratio | 60% | 52% | 67% |
HDT-ASCT = High-dose melphalan with autologous stem cell transplantation; RD = Lenalidomide-Dexamethasone; VD = Bortezomib-Dexamethasone; PD = Pomalidomide-Dexamethasone; VRD = Bortezomib-Lenalidomide-Dexamethasone; Dara = Daratumumab; ACVDL = Doxorubicin-Cyclophosphamide-Bortezomib-Lenalidomide-Dexamethasone